APA

Koller E., Propp S., Zhang H., Zhao C., Xiao X., Chang M., Hirsch S. A., Shepard P. J., Koo S., Murphy C., Glazer R. I. & Dean N. M. (20060413). Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. : Cancer research.

Chicago

Koller Erich, Propp Stephanie, Zhang Hong, Zhao Chenguang, Xiao Xiaokun, Chang MingYi, Hirsch Scott A, Shepard Peter J, Koo Seongjoon, Murphy Cain, Glazer Robert I and Dean Nicholas M. 20060413. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. : Cancer research.

Harvard

Koller E., Propp S., Zhang H., Zhao C., Xiao X., Chang M., Hirsch S. A., Shepard P. J., Koo S., Murphy C., Glazer R. I. and Dean N. M. (20060413). Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. : Cancer research.

MLA

Koller Erich, Propp Stephanie, Zhang Hong, Zhao Chenguang, Xiao Xiaokun, Chang MingYi, Hirsch Scott A, Shepard Peter J, Koo Seongjoon, Murphy Cain, Glazer Robert I and Dean Nicholas M. Use of a chemically modified antisense oligonucleotide library to identify and validate Eg5 (kinesin-like 1) as a target for antineoplastic drug development. : Cancer research. 20060413.